Chemistry Reference
In-Depth Information
9. Rishton GM (1997) Reactive compounds and in vitro false positives in HTS. Drug Discov
Today 2(9):382-384
10. Seidler J et al (2003) Identification and prediction of promiscuous aggregating inhibitors
among known drugs. J Med Chem 46(21):4477-4486
11. McGovern SL et al (2003) A specific mechanism of nonspecific inhibition. J Med Chem
46(20):4265-4272
12. McGovern SL et al (2002) A common mechanism underlying promiscuous inhibitors from
virtual and high-throughput screening. J Med Chem 45(8):1712-1722
13. Kenny BA et al (1998) The application of high-throughput screening to novel lead discovery.
Prog Drug Res 51:245-269
14. Macarron R (2006) Critical review of the role of HTS in drug discovery. Drug Discov Today
11(7-8):277-279
15. Powers R (2009) Advances in nuclear magnetic resonance for drug discovery. Expert Opin
Drug Discov 4(10):1077-1098
16. Pellecchia M et al (2008) Perspectives on NMR in drug discovery: a technique comes of age.
Nat Rev Drug Discov 7(9):738-745
17. Roberts GCK (2000) Applications of NMR in drug discovery. Drug Discov Today 5(6):
230-240
18. Huth JR et al (2004) ALARM NMR: a rapid and robust experimental method to detect
reactive false positives in biochemical screens. J Am Chem Soc 127(1):217-224
19. Dalvit C et al (2006) NMR-based quality control approach for the identification of false
positives and false negatives in high throughput screening. Curr Drug Discov Technol 3(2):
115-124
20. Schade M (2007) Fragment-based lead discovery by NMR. Front Drug Des Discov
3:105-119
21. Zartler ER, Mo H (2007) Practical aspects of NMR-based fragment discovery. Curr Top Med
Chem 7(16):1592-1599
22. Dalvit C (2009) NMR methods in fragment screening: theory and a comparison with other
biophysical techniques. Drug Discov Today 14(21/22):1051-1057
23. Fesik SW (1993) NMR structure-based drug design. J Biomol NMR 3(3):261-269
24. Kubinyi H (1998) Structure-based design of enzyme inhibitors and receptor ligands. Curr
Opin Drug Discov Devel 1(1):4-15
25. Ishihara K et al (2009) Identification of urinary biomarkers useful for distinguishing
a difference in mechanism of toxicity in rat model of cholestasis. Basic Clin Pharmacol
Toxicol 105(3):156-166
26. Ott K-H, Aranibar N (2007) Nuclear magnetic resonance metabonomics: methods for drug
discovery and development. Methods Mol Biol 358:247-271
27. Powers R (2009) NMR metabolomics and drug discovery. Magn Reson Chem 47(S1):
S2-S11
28. Powers R, Mercier KA, Copeland JC (2008) The application of FAST-NMR for the identifi-
cation of novel drug discovery targets. Drug Discov Today 13(3-4):172-179
29. Mercier KA et al (2006) FAST-NMR: functional annotation screening technology using
NMR spectroscopy. J Am Chem Soc 128(47):15292-15299
30. Kitchen DB et al (2004) Docking and scoring in virtual screening for drug discovery:
methods and applications. Nat Rev Drug Discov 3(11):935-949
31. Halperin I et al (2002) Principles of docking: an overview of search algorithms and a guide to
scoring functions. Proteins 47(4):409-443
32. Warren GL et al (2006) A critical assessment of docking programs and scoring functions.
J Med Chem 49(20):5912-5931
33. Hartshorn MJ et al (2007) Diverse, high-quality test set for the validation of protein-ligand
docking performance. J Med Chem 50(4):726-741
34. Jacobsson M et al (2003) Improving structure-based virtual screening by multivariate analy-
sis of scoring data. J Med Chem 46(26):5781-5789
